Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

OKYO Pharma Reports Filing Of An Investigational New Drug (IND) Application For OK-101 To Treat Neuropathic Corneal Pain

Author: Benzinga Newsdesk | October 09, 2023 07:01am

Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

Posted In: OKYO